Published in Cancer Discov on September 07, 2016
The Sequence Alignment/Map format and SAMtools. Bioinformatics (2009) 232.39
Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res (2010) 43.51
STAR: ultrafast universal RNA-seq aligner. Bioinformatics (2012) 25.21
Signatures of mutational processes in human cancer. Nature (2013) 21.63
VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res (2012) 15.90
limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res (2015) 14.81
Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60
voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol (2014) 8.13
Integrative clinical genomics of advanced prostate cancer. Cell (2015) 5.29
Hippo signaling: growth control and beyond. Development (2011) 5.25
The Hippo pathway and human cancer. Nat Rev Cancer (2013) 5.17
The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res (2013) 4.45
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
Human genomics. The human transcriptome across tissues and individuals. Science (2015) 3.53
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell (2015) 2.31
Hippo pathway activity influences liver cell fate. Cell (2014) 2.24
Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia (2011) 2.21
The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell (2014) 2.21
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. JAMA (2015) 2.02
Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactions. Sci Signal (2013) 1.69
Protein kinases of the Hippo pathway: regulation and substrates. Semin Cell Dev Biol (2012) 1.61
Deep Sequencing in Microdissected Renal Tubules Identifies Nephron Segment-Specific Transcriptomes. J Am Soc Nephrol (2015) 1.59
Expanding the histologic spectrum of mucinous tubular and spindle cell carcinoma of the kidney. Am J Surg Pathol (2006) 1.50
Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity. Cancer Res (2011) 1.47
Mutational dynamics between primary and relapse neuroblastomas. Nat Genet (2015) 1.36
PTPN14 interacts with and negatively regulates the oncogenic function of YAP. Oncogene (2012) 1.17
Of mice and men: divergence of gene expression patterns in kidney. PLoS One (2012) 1.15
Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep (2016) 1.15
Defining the protein-protein interaction network of the human hippo pathway. Mol Cell Proteomics (2013) 1.14
The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. Cancer Res (2015) 1.07
Low-grade tubular-mucinous renal neoplasms: morphologic, immunohistochemical, and genetic features. Mod Pathol (2002) 1.06
Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet (2016) 1.05
The expression profiles of nuclear receptors in the developing and adult kidney. Mol Endocrinol (2006) 0.97
The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. Genome Res (2015) 0.97
Mapping RNA-seq Reads with STAR. Curr Protoc Bioinformatics (2015) 0.93
Current and proposed molecular diagnostics in a genitourinary service line laboratory at a tertiary clinical institution. Cancer J (2014) 0.90
Discovering the Hippo pathway protein-protein interactome. Cell Res (2014) 0.90
Human renal cell carcinogenesis is accompanied by a coordinate loss of the tissue specific transcription factors HNF4 alpha and HNF1 alpha. Cancer Lett (1996) 0.89
Hippo signaling influences HNF4A and FOXA2 enhancer switching during hepatocyte differentiation. Cell Rep (2014) 0.88
Best practices recommendations in the application of immunohistochemistry in the kidney tumors: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol (2014) 0.87
Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing. Am J Pathol (2014) 0.86
Hepatocyte nuclear factor 4 alpha is related to survival of the condensed mesenchyme in the developing mouse kidney. Dev Dyn (2010) 0.83
Hepatocyte nuclear factor 4 alpha is associated with mesenchymal-epithelial transition in developing kidneys of C57BL/6 mice. J Vet Med Sci (2010) 0.82
Expression of hepatocyte nuclear factor 4alpha in developing mice. Anat Histol Embryol (2008) 0.82
Mucinous spindle and tubular renal cell carcinoma: analysis of chromosomal aberration pattern of low-grade, high-grade, and overlapping morphologic variant with papillary renal cell carcinoma. Ann Diagn Pathol (2015) 0.82
Expulsive therapy versus early endoscopic stone removal in patients with acute renal colic: a comparison of indirect costs. J Urol (2013) 1.47
Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer. Prostate (2014) 1.10
Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing. Am J Pathol (2014) 0.86
Metastatic renal cell carcinoma, clear cell type, of the parotid gland: a case report, review of literature, and proposed algorithmic approach to salivary gland clear cell neoplasms in fine-needle aspiration biopsies. Diagn Cytopathol (2014) 0.76
Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics. Prostate (2016) 0.75